Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Contineum Therapeutics stock have a consensus rating of "Buy" and an average price target of $18.6, which forecasts a 68.48% increase in the stock price over the next year. The lowest target is $14 and the highest is $23.

Price Target: $18.6 (+68.48%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$14	$18.6	$20	$23
Change	+26.81%	+68.48%	+81.16%	+108.33%

Analyst Ratings

The average analyst rating for Contineum Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	1	1	1	1	1	1
Buy	3	4	4	4	4	3
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeffrey Hung Morgan Stanley	Morgan Stanley	Buy → Hold Downgrades $23 → $14	Buy → Hold	Downgrades	$23 → $14	+26.81%	Jan 8, 2026
Joel Beatty Baird	Baird	Buy Maintains $16 → $14	Buy	Maintains	$16 → $14	+26.81%	Nov 24, 2025
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $25 → $22	Buy	Maintains	$25 → $22	+99.28%	Nov 21, 2025
Faisal Khurshid Leerink Partners	Leerink Partners	Buy Initiates $20	Buy	Initiates	$20	+81.16%	Sep 25, 2025
Jeffrey Hung Morgan Stanley	Morgan Stanley	Buy Maintains $20 → $21	Buy	Maintains	$20 → $21	+90.22%	Aug 18, 2025

More Analyst Ratings

Financial Forecast

• Revenue This Year:
  n/a
• Revenue Next Year:
  n/a
• EPS This Year:
  -2.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	50.00M	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-13.77	-10.81	0.08	-2.18	-2.14	-2.46	-2.46
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	10	10	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-1.25	-2.00
Avg	-2.14	-2.46
Low	-2.27	-3.07

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.